paclitaxel has been researched along with Epithelial Neoplasms in 302 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (3.31) | 18.2507 |
| 2000's | 32 (10.60) | 29.6817 |
| 2010's | 258 (85.43) | 24.3611 |
| 2020's | 2 (0.66) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, DK; Arranz, JA; Coleman, RL; Fujiwara, K; Gabra, H; Ghamande, SA; González-Martín, A; Hanna, R; Herzog, TJ; Jia, Y; Monk, BJ; Pignata, S; Ramsay, L; Rubio, MJ; Scambia, G; Sehouli, J; Slomovitz, B; Tewari, KS; Ushijima, K; Vergote, IB; Vulsteke, C; Weil, SC; Wenham, RM; Zamagni, C | 1 |
| Bender, D; Bookman, MA; Chi, DS; Cohn, DE; Friedlander, M; Gershenson, DM; Gray, HJ; Lee, RB; Lichtman, SM; Lovecchio, JL; Menzin, AW; Mutch, DG; Purdy, C; Secord, AA; Sia, TY; Teoh, DG; Tew, WP; Tewari, KS; Van Le, L; Wahner Hendrickson, AE; Wenham, RM | 1 |
| Alvarez Secord, A; Armstrong, DK; Basen-Engquist, K; Brady, MF; Casey, AC; Chan, JK; Cohn, DE; Coleman, RL; Davidson, SA; DiSilvestro, P; Enserro, D; Fujiwara, K; Herzog, TJ; Huang, HQ; Kim, BG; Kim, JW; Mannel, RS; Nam, JH; Park, SY; Rubin, S; Sabbatini, P; Spirtos, NM; Tewari, KS; Walker, JL | 1 |
| Brown, JM; Brundage, MD; Cook, A; Embleton, AC; Kaplan, RS; Ledermann, JA; Qian, W; Raja, FA; Stark, DP; Swart, AMW; Velikova, G | 1 |
| Balega, J; Elattar, A; Kehoe, S; Nevin, J; Phillips, A; Singh, K; Sundar, S | 1 |
| Armstrong, DK; Ashfaq, R; Basen-Engquist, K; Brady, MF; Chan, JK; Coleman, RL; Davidson, SA; DiSilvestro, P; Fujiwara, K; Herzog, TJ; Huang, H; Kim, BG; Mannel, RS; O'Malley, DM; Rubin, SC; Sabbatini, P; Spirtos, NM; Tewari, KS; Walker, JL | 1 |
| Birrer, M; Brozick, J; Bshara, W; Edwards, RP; Grabosch, S; Lankes, HA; Lugade, A; Ma, T; Moore, K; Odunsi, K; Omilian, A; Strange, M; Stuckey, AR; Tseng, G; Vlad, A; Walker, JL | 1 |
| Kang, S; Kim, SH; Lim, MC; Park, SY; Seo, SS; Song, YJ; Yoo, CW; Yoo, HJ | 1 |
| Bergzoll, C; Eva, L; Jamieson, A; Simcock, B; Sykes, P | 1 |
| Crim, A; Ding, K; Dvorak, J; Gillen, J; Greenwade, M; Gunderson, C; Moore, K; Rowland, M; Ruskin, R; Walter, A | 1 |
| Alberts, DS; Angioli, R; Baldelli, E; Dong, T; Gambara, G; Guillen-Rodriguez, JM; Hodge, KA; Liotta, LA; Memo, M; Odicino, F; Pecorelli, SL; Petricoin, EF; Pierobon, M; Ravaggi, A; Sereni, MI | 1 |
| Boban, T; Boraska Jelavić, T; Brčić, L; Vrdoljak, E | 1 |
| Chen, Y; Teng, NNH; Westhoff, GL | 1 |
| Curry, E; Gabra, H; Janczar, S; Nautiyal, J; Paige, AJ; Sun, M; Xiao, Y; Zanini, E | 1 |
| Fernandes Junior, HJ; Graziani, SR; Kalil Filho, R; Maranhão, RC; Morikawa, AT; Van Eyll, BM; Vital, CG | 1 |
| Jia, L; Jin, H; Lu, Y; Lv, M; Ming, Y; Yu, Y; Zhao, H; Zhao, N; Zheng, Z; Zhou, J | 1 |
| Copeland, NG; Hanash, SM; Hashimoto, K; Jenkins, NA; Katayama, H; Kimura, T; Kobayashi, M; Kodama, M; Kodama, T; Mabuchi, S; Newberg, JY; Rangel, R; Sawada, K; Tien, JC; Wei, Z; Yoshihara, K | 1 |
| Chen, WT; Dombroff, MK; Dong, H; Pearl, ML; Tulley, S; Zhao, Q | 1 |
| Bonetti, A; Giuliani, J | 1 |
| Bun, S; Ebata, T; Fujiwara, Y; Kato, T; Kodaira, M; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yoshida, H; Yunokawa, M | 1 |
| Marth, C; Reimer, D; Zeimet, AG | 1 |
| Chan, JK; Monk, BJ | 1 |
| Guo, Q; Huang, S; Li, Z; Liao, Y; Liu, Y; Lu, L; Sun, H; Wang, X; Zhang, Y; Zhao, L | 1 |
| Aalbers, AGJ; Aaronson, NK; Arts, HJ; de Hingh, IHJT; Hermans, RHM; Kieffer, JM; Koole, SN; Massuger, LFAG; Schagen van Leeuwen, JH; Schreuder, HWR; Sikorska, K; Sonke, GS; Van de Vijver, KK; van der Velden, J; van Driel, WJ; van Tinteren, H; Verwaal, VJ | 1 |
| Banerjee, S; Chen, J; Colombo, N; Gore, M; Gorla, S; Hirte, H; Kaye, S; Naumann, RW; Oza, A; Poondru, S; Sessa, C; Singh, M; Steinberg, J; Van Tornout, J; Yuen, G | 1 |
| Bristow, RE; Burger, RA; Eskander, RN; Fujiwara, K; Glaser, GE; Hamilton, CA; Huh, WK; Kauderer, J; Mannel, RS; O'Malley, DM; Rubin, SC; Stephan, JM; Tewari, KS; Ueland, F | 1 |
| Mandai, M; Matsumura, N; Murakami, K; Nakai, H; Suzuki, A; Takaya, H; Tobiume, T | 1 |
| Dos Santos Guimarães, I; Dos Santos, DZ; Gimba, ERP; Ladislau-Magescky, T; Rangel, LBA; Silva, IV; Sternberg, C; Tessarollo, NG | 1 |
| Akbayir, O; Ayhan, A; Celik, H; Cuylan, ZF; Dede, M; Gungor, T; Gungorduk, K; Kuscu, E; Meydanli, MM; Ozgul, N; Sahin, H; Sari, ME | 1 |
| Hashimoto, H; Kontani, K; Mimura, M; Miyatake, T; Nagamatsu, M; Nishikawa, A; Takeda, M; Yokoi, T | 1 |
| Chen, GP; Chen, YQ; Hu, JL; Liu, NF; Sun, HY; Yang, Y; Yu, H; Zhu, JQ; Zhu, T | 1 |
| Chen, H; Dong, W; Hou, Y; Li, B; Lin, M; Lou, G; Xia, B; Zhang, X | 1 |
| Bodurka, DC; Bookman, MA; Friedlander, M; Geller, M; Glaser, G; Herzog, TJ; Java, JJ; Krivak, TC; Lee, RB; Mutch, DG; O'Malley, DM; Olawaiye, AB; Wenham, RM | 1 |
| Ghaem-Maghami, S; Jung, Y; Lam, EW; Maher, J; Natoli, M; Parente-Pereira, AC; Smith, JR; Wahba, J; Whilding, LM; Zona, S | 1 |
| Beck, HM; Fuh, KC; Guo, L; Hagemann, AR; Ilivicky, AR; Lawrence, JA; Lomonosova, E; McCourt, C; Mills, KA; Mutch, DG; Powell, MA; Quinn, JM; Roach, ST; Starks, CM; Thaker, PH | 1 |
| Hirasawa, T; Iida, T; Ikeda, M; Machida, H; Mikami, M; Shida, M | 1 |
| Komiyama, S; Kubushiro, K; Kugimiya, T | 1 |
| DeFazio, A; Francis, J; Friedlander, M; Goss, G; Jordan, S; O'Brien, S; Obermair, A; Quinn, M; Steer, C; Webb, P; Wyld, D | 1 |
| Castro, C; de León, DC; Gallardo, D; Herrera, LA; López, A; Mendoza, J; Mohar, A; Morales, F; Oñate, LF; Perez, D; Prada, D; Santibáñez, M | 1 |
| Armstrong, DK; Coleman, RL; Phillips, M; Weil, SC; White, AJ | 1 |
| Hoffman, RM; Jung, PS; Kim, DY; Kim, JH; Kim, MB; Kim, YM; Kim, YT; Lee, SW; Nam, JH | 1 |
| Apte, SM; Bou Zgheib, N; Gonzalez-Bosquet, J; Judson, PL; Lancaster, JM; Roberts, WS; Teefey, P; Wenham, RM | 1 |
| Adank, MA; Burger, CW; de Bock, GH; de Hullu, JA; Gaarenstroom, KN; Kriege, M; Mourits, MJ; Reitsma, W; Rijcken, F; Schmidt, MK; Seynaeve, C; Slangen, BF; van Altena, AM; van Beurden, M; Vasen, HF; Vencken, PM; Zweemer, RP | 1 |
| Armstrong, DK; Copeland, LJ; Java, J; Landrum, LM; Lanneau, GS; Mathews, CA; Walker, JL | 1 |
| Bellone, S; Bignotti, E; Buza, N; Cocco, E; Pecorelli, S; Ravaggi, A; Romani, C; Roque, DM; Rutherford, TJ; Santin, AD; Schwartz, PE | 1 |
| Hu, P; Kang, S; Li, Y; Sun, HY; Wang, N; Zhou, RM | 1 |
| Bodnar, L; Grala, B; Kozlowski, W; Smoter, M; Stec, R; Szczylik, C; Zieniuk, K | 1 |
| Chen, KJ; Chen, L; Chen, WY; Chen, X; Jia, YM; Peng, GQ | 1 |
| Alder, H; Baldassarre, G; Belletti, B; Califano, D; Canzonieri, V; Chiappetta, G; Cirombella, R; Croce, CM; Giglio, S; Losito, S; Lovat, F; Onesti, EC; Pellegrini, P; Pignata, S; Sonego, M; Sorio, R; Stoppacciaro, A; Vecchione, A; Volinia, S; Wernicke, D | 1 |
| Markman, M | 2 |
| Dhillon, S | 1 |
| Greenberg, J; Grisaru, D; Inbar, M; Levy, T; Matcejevsky, D; Pelles, S; Safra, T; Shamai, S; Shpigel, S; Veizman, A | 1 |
| Graeser, MK; Jaenicke, F; Mahner, S; Mathey, S; Milde-Langosch, K; Müller, V; Trillsch, F; Woelber, L; Zu Eulenburg, C | 1 |
| Li, D; Yao, X; Zhang, P | 1 |
| Kubushiro, K; Kurasaki, A; Sakurai, N; Takahashi, K; Taoka, H; Yamamoto, Y | 1 |
| Bookman, MA; Brady, MF; Burger, RA; Kong, G; Nguyen, HP; Rhee, J; Sovak, MA | 1 |
| Bean, Y; Beckmann, MW; Beesley, J; Berchuck, A; Brown, R; Camey, ME; Chen, X; Chenevix-Trench, G; Cramer, DW; Cunningham, JM; deFazio, A; Despierre, E; du Bois, A; Ekici, AB; Emmanuel, C; Fasching, PA; Fereday, S; Fridley, BL; Gao, B; Goode, EL; Goodman, MT; Haber, M; Harter, P; Hedditch, EL; Heitz, F; Henderson, MJ; Hogdall, C; Hogdall, E; Jensen, A; Johnatty, SE; Karlan, BY; Kjaer, SK; Lambrechts, S; Law, MH; Lester, J; Levine, DA; Lu, Y; Lurie, G; MacGregor, S; Norris, MD; Paul, J; Pejovic, T; Russell, AJ; Schwaab, I; Shildkraut, J; Terry, KL; Thompson, PJ; Vergote, I; Vierkant, RA; Webb, PM | 1 |
| Aoki, D; Isonishi, S; Jobo, T; Katsumata, N; Kimura, E; Kodama, S; Michimae, H; Ochiai, K; Sugiyama, T; Takahashi, F; Terauchi, F; Yasuda, M | 1 |
| Kruitwagen, RF; Massuger, LF; Ottevanger, PB; van de Laar, R; Van Gorp, T; Zusterzeel, PL | 1 |
| Crivellaro, C; Cuzzocrea, M; Dell'Anna, T; Dolci, C; Fruscio, R; Guerra, L; Messa, C; Milani, R; Signorelli, M; Sina, F | 1 |
| Barker, J; Burrell, M; Feuer, GA; Lakhi, N; Salmieri, S | 1 |
| Leary, A; Lhomme, C; Pautier, P; Tazi, Y | 1 |
| Fujiwara, K; Iwasaki, S; Muraji, M; Nishimura, R; Sudo, T; Ueno, S; Wakahashi, S; Yamaguchi, S | 1 |
| Lawrie, TA; Morrison, J; Rabbie, R; Thoma, C | 1 |
| Ahmed, N; Fraser, FW; Kumar, J; McCulloch, DR; Riley, C; Ward, AC | 1 |
| Walker, JL | 1 |
| Bagnoli, M; Canevari, S; De Cecco, L; Granata, A; Iorio, E; Mezzanzanica, D; Nicoletti, R; Pisanu, ME; Podo, F; Ricci, A; Tinaglia, V | 1 |
| da Costa Miranda, V; da Silva Bessa, LR; da Silva, JR; de Freitas, D; de Paula Carvalho, J; de Souza Fêde, ÂB; Del Pilar Estevez Diz, M; Dos Anjos, CH; Filho, EA; Sanchez, FB | 1 |
| Alvero, AB; Azodi, M; Craveiro, V; Gill, SK; Griffin, B; Holmberg, JC; Joo, WD; Mor, G; Pizzonia, J; Rutherford, T; Silasi, DA; Sumi, NJ; Yang-Hartwich, Y | 1 |
| Hong, JH; Jin, HM; Kim, JW; Lee, JK; Lee, NW; So, KA; Song, JY | 1 |
| Cheng, J; Deng, BF; Huang, JM; Lin, Q; Lu, HY; Ma, SQ; Shi, Y; Wang, MM; Wang, W; Zha, X; Zhang, GN; Zhu, Y | 1 |
| Hay, JW; Mehta, DA | 1 |
| González Ruiz de la Herrán, F; Haya Palazuelo, J; López de la Manzanara Cano, C; Martín Fernández, J; Padilla Valverde, D; Pascual-Ramírez, J; Sánchez García, S; Villarejo Campos, P | 1 |
| Brower, SL; Krivak, TC; Leath, CA; Lele, S; Moore, RG; Richard, S; Secord, AA; Tian, C | 1 |
| Christopoulou, A; Emmanouilidis, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Koinis, F; Papadimitraki, E; Polyzos, A; Samonis, G; Zafeiriou, Z | 1 |
| Bodnar, L; Grala, B; Jakobsen, A; Smoter, M; Stec, R; Steffensen, KD; Szczylik, C; Waldstrøm, M | 1 |
| Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y | 1 |
| Aoki, Y; Asakura, H; Doi, D; Fujita, K; Honma, S; Kamoi, S; Kato, H; Kodama, S; Konishi, H; Matsushima, T; Nakayama, H; Takeshita, T; Tanaka, K; Yahata, T; Yoneyama, K | 1 |
| Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ | 1 |
| Cai, M; Gao, J; Hu, Z; Lin, B; Liu, C; Liu, D; Liu, J; Tan, M; Zhang, D | 1 |
| Benbrook, DM; Ding, K; McMeekin, DS; Moore, KN; Nelson, T; Penaroza, S; Slaughter, KN; Thai, T; Thavathiru, E | 1 |
| Blansit, K; Chan, JK; Herzog, TJ; Hu, L; Kapp, DS; Kiet, T; Monk, BJ; Yu, X | 1 |
| Chang, CL; Chen, CP; Cheng, JT; Lee, WL; Seow, KM; Tsui, KH; Wang, PH; Wang, SY; Yang, LW; Yen, MS | 1 |
| Ansaloni, L; Bogani, G; Coccolini, F; Frigerio, L; Grosso, G; Rossetti, D | 1 |
| Bratos, R; Chiva, L; González-Martín, A; Márquez, R; Sánchez-Lorenzo, L | 1 |
| Bae, DS; Bamias, A; Brize, A; Coleman, RL; Fabbro, M; Fujiwara, K; Herzog, TJ; Karlan, BY; Lhommé, C; Marth, C; Monk, BJ; Navale, L; Oaknin, A; Oza, AM; Poveda, A; Provencher, DM; Raspagliesi, F; Ray-Coquard, I; Redondo, A; Richardson, G; Rincón, DG; Tassoudji, M; Vergote, I; Warner, DJ | 1 |
| Ercoli, A; Fagotti, A; Margariti, PA; Pedone Anchora, L; Petrillo, M; Salutari, V; Scambia, G; Tortorella, L; Zannoni, GF | 1 |
| Barry-O'Crowley, J; Bates, M; Cooke, AA; Costello, KM; d'Adhemar, CJ; D'Arcy, T; Ffrench, B; Finn, S; Flood, B; Gallagher, MF; Gleeson, N; Haley, K; Hennessy, B; Kernan, N; Martin, CM; McCann, A; Murphy, C; O'Byrne, K; O'Donnell, D; O'Leary, JJ; O'Neill, LA; O'Toole, S; Pennington, S; Sheils, O; Smyth, PC; Spillane, CD; Stordal, B | 1 |
| Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q | 1 |
| Braicu, EI; Darb-Esfahani, S; Denkert, C; Fotopoulou, C; Joens, T; Lindhofer, H; Mahner, S; Mellstedt, H; Pietzner, K; Richter, R; Sehouli, J; Woopen, H | 1 |
| Boere, IA; de Gooyer, D; Goey, SH; Kerkhofs, LG; Kok, TC; Look, M; Onstenk, W; Ottevanger, PB; Ruit, JB; ten Bokkel Huinink, D; Valster, FA; van der Burg, ME; van der Torren, AM; van Doorn, HC; van Reisen, AG; Verweij, J | 1 |
| Shen, K; Song, Y; Xia, Z; Xin, X; Zhai, X | 1 |
| Hewidy, M; Shawky, H; Tawfik, H | 1 |
| Byun, HJ; Kim, BR; Lee, SH; Rho, SB; Seo, SH; Yoon, K | 1 |
| Chaudhury, S; Gaikwad, SM; Jinager, A; Maheshwari, A; Ray, P; Singh, RK | 1 |
| Geller, M; Ramakrishnan, S; Rivard, C; Saluja, A; Saluja, M; Schnettler, E; Vogel, RI | 1 |
| Chen, S; Tai, H; Tong, X; Wang, J; Yang, F; Yang, Y; Yiqin, O | 1 |
| Cascales-Campos, PA; Feliciangeli, E; Gil, E; Gil, J; González-Gil, A; López, V; Nieto, A; Parrilla, JJ; Parrilla, P; Ruiz-Pardo, J | 1 |
| Bertrand, M; Colombo, PE; Fabbro, M; Gutowski, M; Labaki, M; Mollevi, C; Mourregot, A; Quenet, F; Rouanet, P; Saint-Aubert, B | 1 |
| Mannel, RS; Moore, KN; Slaughter, KN | 1 |
| Cho, H; Kim, JH; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ | 1 |
| Chang, MC; Chen, CA; Cheng, WF; Chiang, YC; Hsieh, CY; Kuo, KT; Lin, HP; Lu, TP | 1 |
| Bruixola, G; Caballero, J; De La Cueva, H; Díaz, R; Domingo, S; Palomar, L; Santaballa, A | 1 |
| Bonneau, C; Castela, M; Cortez, A; Daraï, E; Geyl, C; Lis, R; Rouzier, R; Touboul, C | 1 |
| Ansaloni, L; Ballerini, A; Bertoli, P; Busci, LM; Cambria, F; Ceresoli, M; Coccolini, F; D'Incalci, M; Frigerio, L; Grosso, G; Lotti, M; Morosi, L; Pisano, M; Rossetti, D; Zucchetti, M | 1 |
| Andrade, C; Clark, RM; del Carmen, MG; Esselen, KM; Foley, OW; Hinchcliff, EM; Horowitz, NS; Rauh-Hain, JA; Vargas, RJ; Winograd, D | 1 |
| Borani, N; Karalök, MA; Keskin, HL; Köse, MF; Özgül, N; Tulunay, HG; Turan, AT; Üreyen, I | 1 |
| Chang, CH; Chen, CC; Chiu, WT; Chou, CY; Hsu, KF; Huang, SC; Huang, YF; Tsai, HY | 1 |
| Bismayer, JA; Dudley, BS; Finney, LH; Gian, VG; Hainsworth, JD; Merritt, WM; Thompson, DS; Whorf, RC | 1 |
| Jansaka, N; Suprasert, P | 1 |
| Barbolina, MV; Choi, J; Gurler, H; Kajdacsy-Balla, AA; Yu, Y | 1 |
| Gaikwad, SM; Ray, P; Sakpal, A; Singh, RK; Thakur, B | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Armstrong, DK; Chan, JK; Herzog, T; Java, JJ; Markman, M; Monk, BJ; Salani, R; Tewari, D | 1 |
| Amiji, MM; Duan, Z; Feng, Y; Foster, R; Gao, Y; Hornicek, FJ; Mankin, HJ; Shen, JK; Yang, X | 1 |
| Amler, LC; Bais, C; Choi, Y; Firestein, R; Fu, L; Fuentes, E; Guan, Y; Huw, LY; Lackner, MR; Lu, S; Rabe, C; Ryner, L; Wang, Y; Xiao, Y | 1 |
| Katsumata, N | 2 |
| Fukuda, T; Hashiguchi, Y; Ichimura, T; Imai, K; Sumi, T; Teramae, M; Yamauchi, M; Yasui, T | 1 |
| Li, PL; Xu, A; Zhang, LY; Zhang, XC | 1 |
| Dandapani, M; Eng, KH; Goldberg, GL; Horwitz, SB; Odunsi, K; Odunsi-Akanji, O; Seagle, BL; Shahabi, S; Yang, CP | 1 |
| Ozbasar, D; Sakarya, DK; Yetimalar, MH | 1 |
| Cohen, JG; Li, AJ; Tran, AQ | 1 |
| Baba, T; Ishikawa, M; Kanato, K; Nakamura, K; Satoh, T; Shibata, T; Takano, M; Tsuda, H; Ushijima, K; Yaegashi, N; Yoshikawa, H | 1 |
| Anuradha, S; Brand, AH; Donovan, PJ; Friedlander, M; Goh, J; Jordan, SJ; Oehler, MK; Quinn, M; Steer, C; Webb, PM | 1 |
| Chang, TH; Chen, CC; Chou, CY; Huang, YF; Wu, YH | 1 |
| Cheng, X; Li, X; Lu, W; Mao, Y; Pan, Q; Wan, X; Xie, X | 1 |
| Koo, YJ; Lim, KT | 1 |
| Duk, MJ; Pasker-de Jong, PC; Schreuder, HW; van Vliet, MM | 1 |
| Cheng, L; Guo, Y; Hu, L; Lv, QL; Qin, CZ; Wu, NY; Zhou, HH | 1 |
| Beumer, JH; Ivy, SP | 1 |
| Bandera, EV; Kushi, LH; Lee, VS; Powell, CB; Rodriguez-Rodriguez, L | 2 |
| Bian, C; Li, L; Yao, K; Yi, T; Zhao, X | 1 |
| Kumar, L; Patel, S; Singh, N | 1 |
| Alexander, H; Banerjee, S; Barton, D; Bodla, S; Georgiou, A; Gore, M; Kaye, S; McLachlan, J; Nobbenhuis, M; Seifert, H | 1 |
| Shi, C; Shuang, T; Wang, D; Wang, M; Zhou, Y | 1 |
| Bae, DS; Cho, YJ; Choi, CH; Choi, JJ; Do, IG; Hong, JE; Jeon, HK; Kim, BG; Kim, MK; Kim, TJ; Kim, WY; Lee, JW; Lee, SH; Lee, YY; Ryu, JY; Yoon, G | 1 |
| Bae, T; Choi, JW; Eum, KH; Kim, S; Lee, JW; Weon, KY | 1 |
| Chang, CF; Chang, MC; Chen, CA; Chen, TC; Cheng, WF; Chiang, YC; Fu, CF; Hsieh, SF; Lin, HW | 1 |
| Ahn, JS; Ahn, MJ; Kim, HS; Lee, JY; Lee, SH; Lim, SH; Moon, SH; Park, K; Sun, JM | 1 |
| Bouchard-Fortier, G; Covens, A; Ferguson, SE; Gien, LT; Kupets, R; Pasetka, M; Pulman, K; Rosen, B; Vicus, D; Vyarvelska, I | 1 |
| Qiang, WA; Tan, W; Wang, SP; Wang, YT; Zhong, ZF | 1 |
| Ge, G; Niu, L; Ren, Y; Yan, Y; Zhang, W; Zou, Y | 1 |
| Kim, JH; Lee, EJ; Lee, TJ; Nguyen, TM; Park, J; Park, MS; Shin, IW | 1 |
| Bae, DS; Byeon, Y; Cho, SK; Cho, YJ; Han, HD; Jeon, HN; Kim, BG; Kim, HS; Lee, JW; Lopez-Berestein, G; Park, YM; Shin, BC; Sood, AK | 1 |
| Eisenmann, KM; Khaing, M; Pettee, KM; Rubinic, K; Ziske, MA | 1 |
| Chiantera, V; Cosentino, F; Costantini, B; Fagotti, A; Fanfani, F; Ferrandina, G; Gallotta, V; Gueli Alletti, S; Margariti, PA; Scambia, G; Tortorella, L; Vizzielli, G | 1 |
| Ezendam, NP; Frielink, LM; Pijlman, BM; Pijnenborg, JM | 1 |
| Chang Chien, CC; Fu, HC; Huang, CC; Lin, H; Liu, JM; Liu, SC; Ma, YY; Ou, YC; Tsai, CC | 1 |
| Alvarez, RD; Becker, DA; Bevis, KS; Boone, JD; Gilbert, AL; Huh, WK; Leath, CA; Straughn, JM; Thomas, ED | 1 |
| Bookman, MA | 3 |
| Chang, WP; Chang, Y; Chang, YH; Chuang, CM; Lee, WH; Lu, CH; Yen, MS | 1 |
| Anttila, M; Breda, E; Hanker, LC; Husain, A; Ojeda, B; Pujade-Lauraine, E; Vuylsteke, P; Wang, Y | 1 |
| Benedetto, C; Canuto, EM; Fishbein, L; Jean, S; Katsaros, D; Li, J; Maxwell, KN; McLane, MW; Mitra, N; Nathanson, KL; Tanyi, JL; Wubbenhorst, B; Zhang, L | 1 |
| Amadio, G; Di Stefano, MG; Fagotti, A; Ferandina, G; Paris, I; Petrillo, M; Salutari, V; Scambia, G | 1 |
| Bayar, A; Bereder, JM; Ferron, G; Glehen, O; Gouy, S; Le Deley, MC; Marchal, F; Morice, P; Pomel, C; Quenet, F | 1 |
| Chang, CL; Chen, JR; Chen, TC; Chien, HJ; Huang, CY; Wang, KL; Weng, CS; Yang, YC | 1 |
| Arévalo-Pérez, J; Barceló, F; Cascales-Campos, P; Gil, E; Gil, J; López-López, V; Nieto, A; Parrilla, P | 1 |
| Liu, CC; Lu, Y; Tang, H; Wang, H; Zhu, J | 1 |
| Hiramatsu, Y; Masuyama, H; Nakamura, K; Nobumoto, E | 1 |
| Otsuka, I; Shoji, K | 1 |
| Chi, DS; Gardner, GJ; Iasonos, A; Kelly, A; Long Roche, K; Mueller, JJ; O'Cearbhaill, RE; Sonoda, Y; Zhou, Q; Zivanovic, O | 1 |
| Choi, KU; Do, KH; Kim, J; Kim, KH; Moon, Y; Park, SH | 1 |
| Alvarez Secord, A; Armstrong, DK; Cohn, DE; Copeland, LJ; Garcia-Soto, AE; Java, JJ; Lele, SB; Nieves Neira, W; Pearson, JM; Tewari, KS; Walker, JL | 1 |
| Bamias, A; Chmielowska, E; Colombo, N; Davidenko, I; DeCensi, A; Gadducci, A; González-Martín, A; Hegg, R; Joly, F; Korach, J; Martin, N; Mendiola, C; Oza, AM; Pautier, P; Robb, S; Selle, F; Zamagni, C; Zvirbule, Z | 1 |
| Bottoni, C; Costantini, B; Fagotti, A; Gallotta, V; Gueli Alletti, S; Nardelli, F; Petrillo, M; Quagliozzi, L; Scambia, G; Vizzielli, G | 1 |
| Bell, J; Chan, JK; Fuh, K; Herzog, T; Java, JJ; Kapp, DS; Monk, BJ; Young, R | 1 |
| Kristeleit, R; Ledermann, JA; MacDonald, N; Marchetti, C; McCormack, M; Mould, T; Olaitan, A; Widschwendter, M | 1 |
| Ataseven, B; du Bois, A; Harter, P; Heitz, F; Hengsbach, A; Kurzeder, C; Prader, S; Schneider, S; Sporkmann, M; Traut, A | 1 |
| Artioli, G; Baldoni, A; Bergamini, A; Breda, E; Cannella, L; Cecere, SC; Colombo, N; Daniele, G; Ferrandina, G; Floriani, I; Greggi, S; Lo Re, G; Lorusso, D; Maltese, G; Nicoletto, MO; Perrone, F; Piccirillo, MC; Pignata, S; Raspagliesi, F; Salutari, V; Scambia, G; Signoriello, S; Tognon, G | 1 |
| Kang, SB; Kim, YM; Kim, YT; Lee, SW | 1 |
| Amant, F; de Haan, J; Fruscio, R; Mhallem, M; Van Calsteren, K; Verheecke, M | 1 |
| Bae, DS; Cho, WC; Cho, YJ; Choi, CH; Choi, JJ; Choi, YL; Heo, EJ; Hong, JE; Jeon, HK; Kim, BG; Kim, TJ; Lee, JW; Lee, YY; Oh, DY; Park, WY; Song, SY | 1 |
| Seagle, BL; Shahabi, S | 1 |
| Decedue, C; Niu, F; Rajewski, RA; Roby, KF; Subramaniam, B; Terranova, PF | 1 |
| Ambrosone, CB; Armstrong, D; Baysal, BE; Darcy, KM; DeLoia, JA; Gallion, H; Krivak, TC; Tian, C | 1 |
| Breda, E; Cognetti, F; Gebbia, V; Lorusso, D; Morabito, A; Perrone, F; Pignata, S; Pisano, C; Savarese, A; Scambia, G; Scollo, P; Signoriello, G; Sorio, R; Vernaglia Lombardi, A | 1 |
| Baba, T; Barnett, JC; Berchuck, A; Chang, JT; Fujii, S; Gray, JW; Gusberg, AH; Huang, Z; Kuo, WL; Lee, PS; Matsumura, N; Mori, S; Murphy, SK; Whitaker, RS | 1 |
| du Bois, A; Harter, P; Huober, J; Loibl, S; Pfisterer, J; Reichardt, VL; Stopfer, P; Wimberger, P | 1 |
| Ino, K; Kajiyama, H; Kikkawa, F; Mizutani, S; Nawa, A; Shibata, K | 1 |
| Cicchillitti, L; Della Corte, A; Di Michele, M; Donati, MB; Ferlini, C; Marcone, S; Rotilio, D; Scambia, G | 1 |
| Bilici, A; Dane, F; Gumus, M; Salepci, T; Salman, T; Seker, M; Turan, C; Unal, O; Ustaalioglu, BB; Yaylaci, M | 1 |
| Hur, SY; Kim, JH; Kim, SJ; Lee, JM; Lee, KH; Lee, SH; Lee, YS; Park, YG; Ryu, KS | 1 |
| Liu, P; Wang, A; Yang, M; Zhang, B; Zhang, X | 1 |
| Coch, C; Eckhardt, M; Hartmann, G; Kübler, K; Kuhn, W; Pölcher, M; Rudlowski, C; Wolfgarten, M | 1 |
| Bast, RC; Brown, GL; Jones, MR; Kavanagh, JJ; Levenback, CF; Meng, L; Moore, CL; Ramirez, PT; Wolf, JL | 1 |
| Campbell, NE; Greenaway, J; Henkin, J; Moorehead, RA; Petrik, J | 1 |
| Cicchillitti, L; Della Corte, A; Di Michele, M; Donati, MB; Rotilio, D; Scambia, G | 1 |
| Bagnato, A; Cianfrocca, R; Di Castro, V; Natali, PG; Rosanò, L; Spinella, F | 1 |
| Liu, J; Matulonis, UA | 1 |
| Aletti, GD; Hartmann, LC | 1 |
| Zorn, KK | 1 |
| Ahn, EH; Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB; Shahzad, MM; Sood, AK | 1 |
| Andreopoulou, E; Blank, S; Borgato, L; Boyd, L; Curtin, J; Levinson, B; Muggia, F; Pothuri, B; Safra, T; Tiersten, A | 1 |
| Cartledge, D; Godwin, AK; Kouadio, A; Zhang, H | 1 |
| Berkowitz, RS; Gao, Z; Garner, EI; Litkouhi, B; McClane, B; Mok, SC; Welch, WR; Xu, X; Zeng, Q | 1 |
| Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
| Bassett, R; Coleman, RL; Dos Reis, R; Harrell, R; Milam, MR; Ramirez, PT; Tao, X | 1 |
| Chicharoen, S; ImAim, C; Liabsuetrakul, T; Reungrairatanaroj, P | 1 |
| Aoki, D; Arao, T; Chiyoda, T; Kataoka, F; Nishimura, S; Nishio, K; Nomura, H; Susumu, N; Tsuda, H | 1 |
| Backes, FJ; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; McCann, GA; O'Malley, DM; Rheaume, PS; Richardson, DL; Salani, R | 1 |
| Amin, MS; Eisenhauer, EA; Hoskins, PJ; Islam, S; O'Brien, AM; Pelletier, LB; Squire, JA; Tu, D; Weberpals, JI | 1 |
| Faught, W; Fung, MF; Hopkins, L; Jolicoeur, L; Latifah, H; Le, T; Weberpals, J | 1 |
| Azodi, M; Baker, L; Husband, A; Kelly, MG; Mor, G; O'Malley, DM; Rutherford, TJ; Schwartz, PE | 1 |
| Atkinson, MA; Ferguson, SE; Helpman, L; Le, L; Mackay, H; Mackean, M; Rana, A; Rogerson, A | 1 |
| Echarri Gonzalez, MJ; Green, R; Muggia, FM | 1 |
| Brady, MF; Cohn, DE; Degeest, K; Hanjani, P; Hiura, M; Kohn, EC; Lee, R; Mannel, RS; Michael, H; Monk, BJ | 1 |
| Cui, H; Kong, L; Li, X; Wang, J; Wang, S; Wei, L; Xu, Q; Zhao, Y | 1 |
| Canuto, EM; Katsaros, D; Lu, L; Rutherford, T; Scarampi, L; Schwartz, P; Yu, H | 1 |
| Fauci, JM; Frederick, PJ; Kilgore, LC; Schneider, KE; Straughn, JM; Subramaniam, A; Whitworth, JM; Zhang, B | 1 |
| Farris, C; Krivak, TC; Lesnock, JL; Markman, M; Smith, KJ | 1 |
| Armstrong, DK; Chernofsky, MR; Farley, JH; Hamilton, CA; Krivak, TC; Markman, M; Maxwell, GL; Miller, A; Miller, C; Ozols, RF; Rose, GS; Stany, MP | 1 |
| Catot, S; Cervantes, A; Chiva, L; de Juan, A; Del Campo, JM; García, Y; García-Donas, J; González-Martín, A; Martínez, S; Oaknin, A; Ponce, J; Poveda, A; Redondo, A; Roda, D | 1 |
| Antsaklis, A; Bamias, A; Dimopoulos, MA; Haidopoulos, D; Karadimou, A; Rodolakis, A; Sotiropoulou, M; Soupos, N; Thomakos, N; Zagouri, F | 1 |
| Han, MH; Hwang, JH; Kang, S; Kim, JH; Kong, SY; Lim, MC; Park, SY; Seo, SS; Yoo, CW; Yoo, HJ | 1 |
| Foretová, L; Fridrichová, P; Laco, J; Melichar, B; Papajík, T; Simkovič, M | 1 |
| Griffin, CL; Hirte, H; Ledermann, JA; Parmar, MK; Qian, W; Raja, FA; Swart, AM | 1 |
| Ardisson, P; Asmane, I; Bajard, A; Bergerat, JP; Coeffic, D; Dufresne, A; Guastalla, JP; Kurtz, JE; Labidi Galy, I; Meeus, P; Moullet, I; Ray-Coquard, I; Tredan, O; Vincent, L | 1 |
| Burkholder, TL; Chen, MD; Gill, JF; Gordon, AN; Hines, J; Homesley, HD; Janicek, MF; Lim, PC; McMeekin, S; Obasaju, CK; Orlando, M; Tai, DF; Teneriello, M; Vaccarello, L; Wang, Y; Zhao, L | 1 |
| Antsaklis, A; Bamias, A; Dimopoulos, MA; Haidopoulos, D; Kakoyianni, K; Kostouros, E; Rodolakis, A; Sakellariou, K; Sotiropoulou, M; Thomakos, N; Trachana, P; Vlahos, G; Zagouri, F | 1 |
| Aghajanian, CA; Bell-McGuinn, KM; Gerst, SR; Grabon, DM; Hensley, ML; Iasonos, A; Konner, JA; Pezzulli, SD; Sabbatini, PJ; Spriggs, DR; Tew, WP; Thaler, H | 1 |
| Brennan, D; Fitzpatrick, P; Furlong, F; Gallagher, M; Maguire, A; Martin, C; McCann, A; McGettigan, P; McGoldrick, A; McGrogan, B; O'Grady, A; O'Leary, J; O'Toole, S; Phelan, S; Prencipe, M; Sheils, O; W Kay, E | 1 |
| Beriwal, S; Edwards, RP; Krivak, TC; Lesnock, JL; McBee, WC; Richard, SD; Skaznik-Wikiel, ME; Zorn, KK | 1 |
| Kim, CW; Kim, E; Kim, YB; Lee, S; Oh, YK; Park, DE; Shim, G; Yu, YH | 1 |
| Aoki, D; Jobo, T; Katsumata, N; Kumagai, S; Michimae, H; Ochiai, K; Shoji, T; Sugiyama, T; Terauchi, F; Yasuda, M | 1 |
| Bellone, S; Bignotti, E; Boeke, M; Cristea, MC; Deng, Y; Glasgow, M; Katsaros, D; Keane, FK; Lindner, R; Lu, L; Muller, RU; Nallur, S; Neuhausen, SL; Paranjape, T; Pecorelli, S; Ratner, ES; Ravaggi, A; Rutherford, TJ; Sand, S; Santin, AD; Schwartz, PE; Slack, FJ; Steele, L; Tassi, RA; Weidhaas, JB; Weitzel, JN; Yao, X; Yu, H; Zelterman, D | 1 |
| Fujiwara, K; Goto, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T; Ohishi, R | 1 |
| Birrer, MJ; Boente, M; Bookman, MA; Brady, MF; Burger, RA; Fleming, GF; Fowler, J; Greer, BE; Homesley, HD; Huang, H; Liang, SX; Mannel, RS; Monk, BJ | 1 |
| Beale, P; Carey, MS; Cervantes, A; Collinson, F; du Bois, A; Essapen, S; Gourley, C; Kimmig, R; Kristensen, G; Kurzeder, C; Ledermann, JA; Leminen, A; Lortholary, A; Mirza, MR; Oza, AM; Parmar, MK; Perren, TJ; Pfisterer, J; Plante, M; Pujade-Lauraine, E; Qian, W; Sehouli, J; Selle, F; Stähle, A; Stark, D; Swart, AM | 1 |
| Armstrong, DK; Birrer, M; Bookman, MA; Darcy, KM; Deloia, J; Dhir, R; Krivak, TC; Muggia, F; Niedernhofer, LJ; Rubatt, JM; Tian, C | 1 |
| Jeon, HW; Jeon, YT; Kim, H; Kim, K; Kim, YB; No, JH | 1 |
| Copeland, LJ; Richardson, DL; Seamon, LG | 1 |
| Hellström, I; Hellström, KE; Wei, H | 1 |
| Boran, N; Celik, B; Hizli, D; Isikdogan, Z; Karabuk, E; Kose, MF; Tulunay, G; Turan, T; Yilmaz, S | 1 |
| Li, XP; Wang, JL; Wang, SJ; Wei, LH; Xu, QY; Zhao, Y | 1 |
| Baumann, K; Belau, A; Burges, A; Canzler, U; du Bois, A; Gropp-Meier, M; Huober, J; Kreienberg, R; Meier, W; Rau, J; Richter, B; Schmalfeldt, B; Schröder, W; Sehouli, J; Stähle, A; Wimberger, P; Wollschlaeger, K | 1 |
| Boere, IA; van der Burg, ME | 1 |
| Kroep, JR | 1 |
| Azodi, M; Glasgow, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Yu, H | 1 |
| Bassi, A; Belotti, D; Castiglioni, V; Cesca, M; Decio, A; Giavazzi, R; Oliva, P; Pesenti, E; Scanziani, E | 1 |
| Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D | 1 |
| Chen, Y; Liu, N; Zhao, J; Zhou, C | 1 |
| Furuya, K; Goto, T; Kato, M; Kita, T; Kudoh, K; Miyamoto, M; Sasaki, N; Takano, M; Watanabe, A; Yoshikawa, T | 1 |
| Bast, RC; Jia, L; Li, X; Liu, J; Mercado-Uribe, I; Ye, Y; Zhang, S | 1 |
| Lichtman, SM; Power, DG; Teo, MY; Tew, WP | 1 |
| Lowe, MP; Schwartzberg, LS; Stepanski, EJ; Tillmanns, TD; Walker, MS | 1 |
| Li, H; Li, J; Liu, G; Yin, D; Zhang, J; Zhang, S; Zhang, W; Zhao, J | 1 |
| Abdulkadir, L; Amant, F; Berteloot, P; Cadron, I; Despierre, E; Leunen, K; Neven, P; Vergote, I | 1 |
| Aneke, H; Curtin, NJ; Edmondson, RJ; Elattar, A; Maxwell, P; McCluggage, WG; Mukhopadhyay, A; Plummer, ER; Quinn, JE; Soohoo, S; Uzir, B | 1 |
| Li, GT | 1 |
| Auranen, A; Carpén, O; Grénman, S; Hynninen, J; Lavonius, M; Oksa, S | 1 |
| Butler-Manuel, S; Essapen, S; Larbi, E; Madhuri, K; Michael, A; Tailor, A | 1 |
| Liu, P; Mao, HL; Pang, Y; Wang, Y; Yang, F; Zhang, X; Zheng, J | 1 |
| Duan, Z; Hu, P; Yue, Y; Zhou, X | 1 |
| Bagnato, A; Baumann, K; Cognetti, F; Colombo, N; Harter, P; Mari, E; McIntosh, S; Nathan, F; Pemberton, K; Savarese, A; Scambia, G; Sehouli, J; Sorio, R; Wimberger, P | 1 |
| Cao, Y; Han, Y; Huang, H; Qu, L; Shou, C; Xiao, Z; Zhang, W | 1 |
| Chang, MC; Chen, CA; Chen, PJ; Cheng, WF; Chiang, YC; Hsieh, CY; Wu, MM | 1 |
| Bickel, LE; Connolly, DC; Do, TV; Ecsedy, JA; Godwin, AK; Golemis, EA; Howe, C; Hua, X; Klein-Szanto, AJ; Litwin, S; Maglaty, M; O'Brien, SW; Pathak, HB; Schilder, RJ; Xiao, F | 1 |
| Asai, M; Asai, N; Enomoto, A; Horio, M; Kato, T; Kikkawa, F; Mii, S; Murakumo, Y; Shibata, K; Takahashi, M | 1 |
| Chu, P; Ghatage, P; Glaze, S; Nation, J; Nelson, G; Teitelbaum, L | 1 |
| Chen, L; Gong, L; Liang, L; Lin, F; Liu, N; Pan, S; Yan, X; Zhang, Q; Zhao, H; Zheng, F | 1 |
| Ahiskali, R; Celikel, T; Ceyhan, BB; Duman, D; Duman, DG | 1 |
| Cruickshank, ME; Delaney, E; Hutcheon, AW; McNally, OM; Parkin, DE; Petty, RD | 1 |
| Lane, SR; Ross, GA; ten Bokkel Huinink, W | 1 |
| Baba, T; Goto, M; Nonogaki, T; Tamai, A; Ueda, M; Utsunomiya, Y | 1 |
| Bolis, G; Cipriani, S; Conta, E; Franchi, M; Guarnerio, P; Mangili, G; Melpignano, M; Parazzini, F; Polverino, G; Presti, M; Raspagliesi, F; Richiardi, G; Scarfone, G; Tateo, S; Villa, A | 1 |
| Apolone, G; Buda, A | 1 |
| Cosio, S; Cristofani, R; Frassi, E; Fuso, L; Gadducci, A; Landoni, F; LaPresa, MT; Maggino, T; Maggioni, A; Sartori, E; Zola, P | 1 |
| Geisler, JP; Manahan, KJ; Wiemann, MC | 1 |
| Akçay, T; Alademir, Z; Arvas, M; Aydinli, K; Demirkiran, F; Dinçer, Y; Kösebay, D | 1 |
| Adams, JM; Beaudoin, B; Bouillet, P; Degenhardt, K; Nelson, DA; Nieves-Neira, W; Tan, TT; Villunger, A; White, E | 1 |
| Kietpeerakool, C; Srisomboon, J; Suprasert, P | 1 |
| Burges, A; du Bois, A; Gropp, M; Harter, P; Huober, J; Pfisterer, J; Schade-Brittinger, C; Schmalfeldt, B; Staehle, A; Wollschlaeger, K | 1 |
| DeNardo, G; DeNardo, S; Lamborn, K; Miers, L; Natarajan, A; Richman, C; Yuan, A | 1 |
| Bae, DS; Kim, BG; Lee, JH; Lee, JW; Lee, SJ; Park, CS | 1 |
| Gregoire, V; Machiels, JP; Pierard, S; Weynand, B | 1 |
| Brown, JV; Goldstein, BH; Graham, C; Hu, JC; Markman, M; Micha, JP; Rettenmaier, MA | 1 |
| Camara, O; Fedders, M; Hartmann, M; Kath, R; Oelschläger, H; Schneider, A | 1 |
| Dragounová, E; Dvorák, J; Hyspler, R; Kalábová, H; Melichar, B; Tichá, A | 1 |
| Katsaros, D; Mor, G; Puopolo, M; Rigault de la Longrais, IA; Rutherford, TJ; Schwartz, P; Smith, S; Su, D; Yu, H | 1 |
| Ferrell, B; Leong, L; Lowe, T | 1 |
| Colombo, N; Fossati, R; Fruscio, R; Garbi, A; Ieda', N; Lissoni, AA; Mangioni, C; Torri, V | 1 |
| Capizzi, E; De Iaco, P; Fiorentino, M; Gabusi, E; Grigioni, AD; Rosati, M; Zamagni, C | 1 |
| Plaxe, SC | 1 |
| Hurwitz, HI; McGuire, WP | 1 |
| Burkhart, CA; Haber, M; Horwitz, SB; Kavallaris, M; Kuo, DY; Norris, MD; Regl, DL | 1 |
| Elbendary, A; Herzog, TJ; Mutch, DG; Rader, JS; Swisher, EM | 1 |
| Benito, D; Casado, A; Cervantes, A; del Campo, JM; Escobedo, A; Massuti, B; Mendiola, C; Moyano, A; Ojeda, B; Poveda, A | 1 |
| Aravantinos, G; Athanassiadis, A; Bafaloukos, D; Bamia, C; Fountzilas, G; Karphathios, S; Kosmidis, P; Papakostas, P; Pavlidis, N; Skarlos, DV; Stathopoulos, GP | 1 |
| Abu-Rustum, NR; Aghajanian, C; Barakat, RR; Fennelly, D; Shapiro, F; Spriggs, D | 1 |
| Ozols, RF | 1 |
| Cain, JM; Figge, D; Goff, BA; Greer, B; Seewaldt, VL; Tamimi, H | 1 |
| Cohen, P; de Leon, CG; Edwards, CL; Finnegan, MB; Forman, A; Freedman, RS; Hord, M; Kavanagh, JJ; Kim, EE; Kudelka, AP; Tresukosol, D; Varma, D; Verschraegen, CF | 1 |
| Kuwahara, M; Motohiro, A; Takahashi, N; Tsukamoto, S; Ueda, H | 1 |
| Fracasso, PM | 1 |
| Bolis, G; Carmichael, J; Coleman, R; Davidson, N; Fields, SZ; Gordon, A; Gore, M; Héron, JF; Malfetano, J; Malmström, H; Ross, G; Scarabelli, C; Spaczynski, M; ten Bokkel Huinink, W; Vennin, P | 1 |
| Favaudon, V; Hennequin, C | 1 |
28 review(s) available for paclitaxel and Epithelial Neoplasms
| Article | Year |
|---|---|
Front-line therapy of advanced epithelial ovarian cancer: standard treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2017 |
Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Female; Humans; Infusions, Parenteral; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2017 |
Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Practice Guidelines as Topic | 2013 |
Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Evidence-Based Medicine; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2013 |
Ovarian pulmonary-type small cell carcinoma: case report and review of the literature.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Neuroendocrine; Carcinoma, Ovarian Epithelial; Carcinoma, Small Cell; Carrier Proteins; Female; Humans; Keratins; Lung; Middle Aged; Neoplasms, Glandular and Epithelial; Neural Cell Adhesion Molecules; Ovarian Neoplasms; Paclitaxel; Tomography, X-Ray Computed; Ubiquitin-Protein Ligases | 2013 |
Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic | 2013 |
Intraperitoneal chemotherapy requires expertise and should be the standard of care for optimally surgically resected epithelial ovarian cancer patients.
Topics: Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Standard of Care; Treatment Outcome | 2013 |
Intraperitoneal chemotherapy in advanced epithelial ovarian cancer: a survey.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Analysis | 2014 |
First-line and maintenance therapy for ovarian cancer: current status and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors | 2014 |
Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2014 |
Maintenance chemotherapy in the management of epithelial ovarian cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Maintenance Chemotherapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines | 2015 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
Dose-dense approaches to ovarian cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2015 |
Novel directions in adjuvant chemotherapy for early stage epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Fertility Preservation; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2015 |
Optimal primary therapy of ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality Improvement | 2016 |
Ovarian cancer in pregnancy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Female; Gestational Age; Humans; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Patient Preference; Pregnancy; Pregnancy Complications, Neoplastic | 2017 |
Syngeneic mouse model of epithelial ovarian cancer: effects of nanoparticulate paclitaxel, Nanotax.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Delivery Systems; Female; Humans; Injections, Intralesional; Injections, Intraperitoneal; Mice; Nanoparticles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Transplantation, Isogeneic | 2008 |
New advances in ovarian cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Female; Humans; Infusions, Parenteral; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Poly Adenosine Diphosphate Ribose; Proteins | 2010 |
Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2011 |
Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2011 |
First-line chemotherapy in epithelial ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Topotecan; Vascular Endothelial Growth Factor A | 2012 |
Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Female; Humans; Laparotomy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyglutamic Acid; Second-Look Surgery | 2012 |
Review of dose-intense platinum and/or paclitaxel containing chemotherapy in advanced and recurrent epithelial ovarian cancer.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Recurrence | 2012 |
Chemotherapy for ovarian cancer: an evidence-based approach.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Time Factors | 2004 |
Quality-of-life issues in the management of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Disease Progression; Docetaxel; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Taxoids | 2007 |
Primary chemotherapy in epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 1994 |
Future directions in the chemotherapy of ovarian cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Forecasting; Gemcitabine; Humans; Injections, Intraperitoneal; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Vinblastine; Vinorelbine | 1997 |
Overcoming drug resistance in ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Maximum Tolerated Dose; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2001 |
62 trial(s) available for paclitaxel and Epithelial Neoplasms
| Article | Year |
|---|---|
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Recurrence | 2023 |
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Reoperation; Survival Analysis | 2019 |
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Remission Induction | 2017 |
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult | 2017 |
Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Lipids; Nanoparticles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2017 |
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Intention to Treat Analysis; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Analysis | 2018 |
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pyrazines; Treatment Outcome; Young Adult | 2018 |
Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Young Adult | 2018 |
Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2018 |
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2013 |
Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Ovarian Epithelial; Chromatography, High Pressure Liquid; Cisplatin; Drug Administration Schedule; Drug Interactions; Female; Half-Life; Humans; Infusions, Intravenous; Liver; Metabolic Clearance Rate; Models, Biological; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Saponins; Triterpenes | 2014 |
Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Observer Variation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Radiography; Single-Blind Method | 2013 |
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models | 2013 |
Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Salvage Therapy; Taxoids | 2014 |
A phase II study of paclitaxel and carboplatin with a biweekly schedule in patients with epithelial ovarian cancer: Gynecologic Cancer Network trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2014 |
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Sorafenib | 2014 |
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Topics: Aged; Angiogenesis Inhibitors; Angiopoietin-1; Angiopoietin-2; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Double-Blind Method; Edema; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Recombinant Fusion Proteins; Withholding Treatment | 2014 |
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult | 2014 |
Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Europe; Fatigue; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Middle Aged; Nausea; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Time Factors; Treatment Outcome; Vomiting; Young Adult | 2014 |
Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2014 |
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Paclitaxel; Prospective Studies; Thymus Neoplasms | 2015 |
Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Body Image; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Length of Stay; Middle Aged; Neoplasms, Glandular and Epithelial; Operative Time; Ovarian Neoplasms; Paclitaxel; Postoperative Complications; Quality of Life; Young Adult | 2016 |
Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Topotecan | 2016 |
Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Hyperthermia, Induced; Maintenance Chemotherapy; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2016 |
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Young Adult | 2017 |
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cytoreduction Surgical Procedures; Feasibility Studies; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2017 |
An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016).
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Micelles; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Republic of Korea | 2017 |
Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide | 2008 |
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Survival Analysis; Treatment Outcome | 2009 |
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Dose-Response Relationship, Drug; Female; Genital Neoplasms, Female; Humans; Indoles; Maximum Tolerated Dose; Middle Aged; Neoplasms, Glandular and Epithelial; Paclitaxel; Treatment Outcome | 2010 |
Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Case-Control Studies; Chemotherapy, Adjuvant; Feasibility Studies; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2010 |
Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Early Termination of Clinical Trials; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Glutathione; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Polyethylene Glycols; Survival Analysis; Treatment Failure | 2010 |
Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Piperazines; Pyrimidines; Salvage Therapy | 2010 |
Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Isoflavones; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Taxoids; Treatment Failure; Treatment Outcome | 2011 |
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2011 |
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Survival Rate | 2011 |
Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: a GEICO study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Administration Schedule; Feasibility Studies; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Outpatients; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Spain; Treatment Outcome | 2011 |
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Induction Chemotherapy; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult | 2011 |
Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Pilot Projects | 2011 |
Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Hemoglobins; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2011 |
Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2012 |
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Survival Analysis; Young Adult | 2011 |
A phase 3 trial of bevacizumab in ovarian cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Survival Analysis | 2011 |
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Piperidines; Prospective Studies; Pyridines; Survival Analysis; Young Adult | 2012 |
Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Treatment Outcome | 2013 |
Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; DNA Breaks, Double-Stranded; Enzyme Inhibitors; Female; Homologous Recombination; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors | 2012 |
Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?
Topics: Abdominal Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2013 |
A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-O
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Placebos; Pyrrolidines; Young Adult | 2013 |
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Disease Progression; Drug Administration Schedule; Female; Humans; Incidence; Infusions, Intravenous; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Sensitivity and Specificity; Survival Analysis; Topotecan | 2004 |
Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Survival Rate | 2004 |
Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cisplatin; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2006 |
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Serous; Epirubicin; Female; Follow-Up Studies; Humans; Ifosfamide; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Rate; Time Factors | 2008 |
Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease Progression; DNA, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Survival Analysis; Treatment Outcome | 2008 |
Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Analysis; Topotecan; Treatment Outcome | 1997 |
Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Incidence; Infusions, Intravenous; Laparotomy; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Reoperation; Spain; Survival Rate; Thrombocytopenia; Treatment Outcome | 1997 |
Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cause of Death; Cisplatin; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Greece; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Remission Induction; Survival Rate; Thrombocytopenia | 1997 |
Salvage weekly paclitaxel in recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; CA-125 Antigen; Cohort Studies; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fever; Follow-Up Studies; Hospitalization; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Remission Induction; Retrospective Studies; Salvage Therapy; Tomography, X-Ray Computed | 1997 |
Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Survival Rate; Taxoids | 1996 |
Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cross-Over Studies; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Europe; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Survival Rate; Topotecan; United States | 2001 |
212 other study(ies) available for paclitaxel and Epithelial Neoplasms
| Article | Year |
|---|---|
The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2023 |
Reporting 'Denominator' data is essential for benchmarking and quality standards in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Female; Guideline Adherence; Gynecologic Surgical Procedures; Gynecology; Humans; Medical Oncology; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Surgical Oncology; Survival Analysis; Treatment Outcome | 2017 |
Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Catheters, Indwelling; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Randomized Controlled Trials as Topic; Tumor Microenvironment | 2017 |
Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Carboplatin; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Practice Guidelines as Topic; Retrospective Studies; Survival Rate | 2017 |
Subtypes of stage IV ovarian cancer; response to treatment and patterns of disease recurrence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; New Zealand; Ovarian Neoplasms; Paclitaxel; Pleural Effusion, Malignant; Prognosis; Retrospective Studies; Treatment Outcome | 2017 |
Evaluation of the efficacy and toxicity profile associated with intraperitoneal chemotherapy use in older women.
Topics: Adenocarcinoma, Clear Cell; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2017 |
Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.
Topics: Adult; Aged; Aged, 80 and over; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease Progression; Drug Resistance, Neoplasm; Epithelium; Female; Forkhead Box Protein O1; Forkhead Box Protein O3; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Protein Array Analysis; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Young Adult | 2017 |
Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel-carboplatin combination therapy in patients with epithelial ovarian cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Erythrocytes, Abnormal; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2017 |
Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Forkhead Box Protein M1; Humans; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Thiostrepton | 2017 |
WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response.
Topics: Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; RNA, Small Interfering; Tumor Suppressor Proteins; WW Domain-Containing Oxidoreductase | 2017 |
Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glucosides; Glycolysis; Herbal Medicine; Humans; Hyaluronan Receptors; Hydrolyzable Tannins; Neoplasm Proteins; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proteomics; Signal Transduction; STAT3 Transcription Factor | 2017 |
In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.
Topics: Apoptosis; beta Karyopherins; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Humans; Ivermectin; Loss of Function Mutation; Neoplasms, Glandular and Epithelial; Oncogenes; Ovarian Neoplasms; Paclitaxel; RNA, Small Interfering | 2017 |
iCTC drug resistance (CDR) Testing ex vivo for evaluation of available therapies to treat patients with epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neoplastic Cells, Circulating; Ovarian Neoplasms; Paclitaxel | 2017 |
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Costs; European Union; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Survival Rate; Tetrahydroisoquinolines; Trabectedin | 2017 |
The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies | 2017 |
Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Hypoxia; Cell Line, Tumor; CSK Tyrosine-Protein Kinase; Drug Resistance, Neoplasm; Drug Synergism; Female; Flavonoids; G2 Phase Cell Cycle Checkpoints; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; M Phase Cell Cycle Checkpoints; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2018 |
Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2018 |
Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Metformin; Neoplasms, Glandular and Epithelial; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Survival Rate | 2018 |
Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Outcome Assessment, Health Care; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Young Adult | 2018 |
Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies | 2016 |
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Survival Rate; Topotecan | 2017 |
Upregulation of miR-874-3p and miR-874-5p inhibits epithelial ovarian cancer malignancy via SIK2.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; MicroRNAs; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Protein Binding; Protein Serine-Threonine Kinases; Transfection; Up-Regulation | 2018 |
Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; B7-H1 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Drug Combinations; Drug Synergism; Female; Humans; Immunotherapy; Mice; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2018 |
SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.
Topics: Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Ovarian Epithelial; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Neoplasm; Tubulin Modulators; Xenograft Model Antitumor Assays | 2018 |
Impact of Adding Bevacizumab to Paclitaxel + Carboplatin for Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Propensity Score Matching Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Propensity Score; Retrospective Studies; Time Factors; Treatment Outcome | 2018 |
Safety and efficacy of neoadjuvant chemotherapy containing bevacizumab and interval debulking surgery for advanced epithelial ovarian cancer: A feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cytoreduction Surgical Procedures; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Safety | 2018 |
Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Guideline Adherence; Humans; Logistic Models; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Practice Guidelines as Topic; Practice Patterns, Physicians'; Registries | 2013 |
The MAD1 1673 G → A polymorphism alters the function of the mitotic spindle assembly checkpoint and is associated with a worse response to induction chemotherapy and sensitivity to treatment in patients with advanced epithelial ovarian cancer.
Topics: Biomarkers, Pharmacological; Calcium-Binding Proteins; Carcinoma, Ovarian Epithelial; Cell Cycle Proteins; Chromosomal Instability; Female; Genetic Association Studies; Humans; M Phase Cell Cycle Checkpoints; Mad2 Proteins; Microtubules; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Nocodazole; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Repressor Proteins | 2013 |
Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Disease-Free Survival; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Tumor Cells, Cultured | 2013 |
Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Administration Schedule; Drug Tolerance; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Netherlands; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival; Treatment Outcome | 2013 |
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Lymphatic Metastasis; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2013 |
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Epothilones; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Microtubules; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Taxoids; Tubulin; Tubulin Modulators | 2013 |
DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; Female; Genotype; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Survival; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2013 |
Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Female; Gene Expression; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; tau Proteins; Treatment Outcome | 2013 |
A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis.
Topics: Antineoplastic Agents; Blotting, Western; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Coculture Techniques; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; MicroRNAs; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Vascular Endothelial Growth Factor B; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Weekly carboplatin with paclitaxel compared to standard three-weekly treatment in advanced epithelial ovarian carcinoma--a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Survival Rate | 2014 |
Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Receptor, Platelet-Derived Growth Factor beta; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
The overexpression of P21-activated kinase 5 (PAK5) promotes paclitaxel-chemoresistance of epithelial ovarian cancer.
Topics: Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; p21-Activated Kinases; Paclitaxel; RNA Interference | 2013 |
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Carcinoma, Ovarian Epithelial; Disease Progression; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Pharmacogenetics; Polymorphism, Single Nucleotide; Proportional Hazards Models | 2013 |
The role of surgery in the management of patients with platinum-sensitive recurrent ovarian cancer: survey among Dutch gynecologists and medical oncologists.
Topics: Antineoplastic Combined Chemotherapy Protocols; Attitude of Health Personnel; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Data Collection; Female; Gynecology; Humans; Medical Oncology; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Netherlands; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Surveys and Questionnaires | 2013 |
Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Perioperative and clinical outcomes in the management of epithelial ovarian cancer using a robotic or abdominal approach.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Gynecologic Surgical Procedures; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Robotics; Treatment Outcome | 2013 |
[Chemotherapy in epithelial ovarian cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2013 |
Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2013 |
Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-6; Janus Kinase 2; Neoplasm Grading; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Receptors, Colony-Stimulating Factor; Signal Transduction; STAT3 Transcription Factor | 2014 |
Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.
Topics: Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Choline; Choline Kinase; Down-Regulation; Doxorubicin; Female; Humans; Lipid Metabolism; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphorylcholine; Platinum; RNA Interference; Signal Transduction; Transcriptome | 2014 |
Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis | 2014 |
Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; HEK293 Cells; Humans; Hyaluronan Receptors; Mice; Mice, Nude; Myeloid Differentiation Factor 88; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Phenotype; Recurrence; Snail Family Transcription Factors; Transcription Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cohort Studies; Disease-Free Survival; Female; Humans; Leukocytosis; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Preoperative Period; Proportional Hazards Models; Retrospective Studies; Young Adult | 2014 |
Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Proliferation; Cholinergic Antagonists; Drug Resistance, Neoplasm; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Female; Humans; Interleukin-6; Lactones; Lymphocyte Antigen 96; Molecular Docking Simulation; Myeloid Differentiation Factor 88; Neoplasms, Glandular and Epithelial; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Protein Conformation; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sesquiterpenes; Signal Transduction; Toll-Like Receptor 4; Tumor Cells, Cultured | 2014 |
Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biosimilar Pharmaceuticals; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Cohort Studies; Cost-Benefit Analysis; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2014 |
Security and efficiency of a closed-system, turbulent-flow circuit for hyperthermic intraperitoneal chemotherapy after cytoreductive ovarian surgery: perioperative outputs.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2014 |
A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prospective Studies; ROC Curve; Survival Analysis; Treatment Outcome | 2014 |
Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; tau Proteins; Treatment Outcome | 2014 |
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
Beclin 1 expression in ovarian tissues and its effects on ovarian cancer prognosis.
Topics: Adolescent; Adult; Aged; Apoptosis Regulatory Proteins; Beclin-1; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Membrane Proteins; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Prognosis; Young Adult | 2014 |
Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
Topics: Adiposity; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Body Mass Index; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Intra-Abdominal Fat; Middle Aged; Multivariate Analysis; Neoplasms, Glandular and Epithelial; Obesity; Ovarian Neoplasms; Overweight; Paclitaxel; Pilot Projects; Prognosis; Proportional Hazards Models; Retrospective Studies; Subcutaneous Fat; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cost-Benefit Analysis; Disease-Free Survival; Female; Health Care Costs; Humans; Middle Aged; Models, Economic; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Vascular Endothelial Growth Factor A | 2014 |
Effect of gonadotropin-releasing hormone agonist on ES-2 ovarian cancer cells.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cytotoxins; Dose-Response Relationship, Drug; Drug Synergism; Female; Gonadotropin-Releasing Hormone; Humans; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Receptors, LHRH | 2014 |
Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Cohort Studies; Cytoreduction Surgical Procedures; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Treatment Outcome; Tumor Burden | 2014 |
The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Immunohistochemistry; MicroRNAs; Middle Aged; Myeloid Differentiation Factor 88; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Phenotype; Prognosis; RNA, Small Interfering; Signal Transduction; Survival Analysis; Toll-Like Receptor 4 | 2014 |
Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Adhesion Molecules; Epithelial Cell Adhesion Molecule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Prognosis; Tissue Banks; Treatment Outcome | 2014 |
Sequential combination of flavopiridol with Taxol synergistically suppresses human ovarian carcinoma growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Synergism; Female; Flavonoids; Humans; In Situ Nick-End Labeling; Mice; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Piperidines; Xenograft Model Antitumor Assays | 2015 |
The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Movement; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred BALB C; Mice, Nude; Multiprotein Complexes; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphoprotein Phosphatases; Phosphoproteins; Phosphorylation; Ribosomal Protein S6 Kinases; Signal Transduction; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2014 |
IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Podophyllotoxin; Proteasome Endopeptidase Complex; Receptor, IGF Type 1 | 2014 |
Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Electric Impedance; Epoxy Compounds; Female; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Organophosphates; Ovarian Neoplasms; Paclitaxel; Phenanthrenes; Prodrugs; Xenograft Model Antitumor Assays | 2014 |
Variation and prognostic value of serum plasminogen activator inhibitor-1 before and after chemotherapy in patients with epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; China; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Plasminogen Activator Inhibitor 1; Prognosis; Retrospective Studies; Survival Analysis | 2014 |
The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2015 |
Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Carcinosarcoma; Cohort Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Reoperation; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Taxoids | 2014 |
Establishment of a New Ovarian Cancer Cell Line CA5171.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Shape; Cisplatin; Class I Phosphatidylinositol 3-Kinases; DNA Copy Number Variations; Doxorubicin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phenotype; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; PTEN Phosphohydrolase; Tumor Suppressor Protein p53 | 2015 |
Feasibility and safety of a modified outpatient regimen with intravenous/intraperitoneal chemotherapy for optimally debulked stage III ovarian cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Feasibility Studies; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome | 2015 |
Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Humans; Hyaluronan Receptors; Interleukin-6; Interleukin-8; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2015 |
Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Cisplatin; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Peritoneum | 2015 |
Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Prognosis; Proportional Hazards Models | 2015 |
Addition of epirubicin to conventional chemotherapy in patients with advanced ovarian cancer: sequential therapy -a retrospective evaluation. .
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Young Adult | 2014 |
FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Humans; Immunohistochemistry; Mice, Inbred NOD; Mice, SCID; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; RNA Interference; Survival Analysis; Thiostrepton; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Survival Rate; Tertiary Care Centers | 2014 |
Three-dimensional collagen type I matrix up-regulates nuclear isoforms of the microtubule associated protein tau implicated in resistance to paclitaxel therapy in ovarian carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Cell Culture Techniques; Collagen Type I; Drug Resistance, Neoplasm; Female; Gene Silencing; Humans; Immunohistochemistry; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Isoforms; RNA Interference; RNA, Small Interfering; tau Proteins | 2015 |
Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Differentiation; Cell Line, Tumor; Cell Survival; Cisplatin; Female; Humans; Mice; Myeloid Differentiation Factor 88; Neoplasms, Glandular and Epithelial; NF-kappa B; Ovarian Neoplasms; Paclitaxel; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2015 |
Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chi-Square Distribution; Cisplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasms, Glandular and Epithelial; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2015 |
Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Recurrence; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Adhesion Molecules; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fibroblasts; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Transcriptome; Treatment Outcome; Tumor Microenvironment; Up-Regulation | 2015 |
Primary peritoneal cancer: study of 14 cases and comparison with epithelial ovarian cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Survival Rate | 2015 |
Involvement of GRP78 in the Resistance of Ovarian Carcinoma Cells to Paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Female; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering | 2015 |
TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.
Topics: Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Epothilones; Female; Genes, p53; Humans; Middle Aged; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Tubulin Modulators; Tumor Suppressor Protein p53 | 2015 |
Impact of obesity on secondary cytoreductive surgery and overall survival in women with recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Obesity; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate | 2015 |
A non-randomized confirmatory study regarding selection of fertility-sparing surgery for patients with epithelial ovarian cancer: Japan Clinical Oncology Group Study (JCOG1203).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Female; Fertility; Humans; Infertility, Female; Japan; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Salpingostomy; Treatment Outcome | 2015 |
Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Time Factors | 2016 |
COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization.
Topics: Antineoplastic Agents; Binding Sites; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Cisplatin; Collagen Type XI; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gene Expression Profiling; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; RNA Interference; RNA, Messenger; RNA, Small Interfering; Ubiquitination | 2015 |
Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cyclin G1; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genetic Loci; Humans; Methylation; MicroRNAs; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; RNA Interference; RNA, Messenger | 2015 |
Toxicity of intraperitoneal chemotherapy and risk factors for severe toxicity in optimally debulked ovarian cancer patients.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Catheter Obstruction; Catheters, Indwelling; Chemotherapy-Induced Febrile Neutropenia; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Diarrhea; Disease-Free Survival; Female; Humans; Ileus; Infusions, Parenteral; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Risk Factors; Survival Rate; Vomiting; Withholding Treatment | 2015 |
Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cyclophosphamide; Cytoreduction Surgical Procedures; Delivery of Health Care; Disease-Free Survival; Female; Follow-Up Studies; Health Status; Hospitals, Teaching; Humans; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Netherlands; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate | 2015 |
Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Bone Marrow; Carboplatin; Carcinoma, Ovarian Epithelial; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Leukocyte Count; Leukopenia; Middle Aged; Neoplasms, Glandular and Epithelial; Neutrophils; Ovarian Neoplasms; Paclitaxel; Paresthesia; Pharmacogenomic Variants; Prospective Studies | 2016 |
Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area : Are We There Yet?
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cisplatin; Drug Dosage Calculations; Humans; Neoplasms, Glandular and Epithelial; Obesity; Ovarian Neoplasms; Paclitaxel | 2015 |
Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; California; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Drug Dosage Calculations; Health Maintenance Organizations; Humans; Logistic Models; Middle Aged; Multivariate Analysis; Neoplasms, Glandular and Epithelial; Obesity; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Registries; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2015 |
Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; China; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome | 2016 |
Metformin and epithelial ovarian cancer therapeutics.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Metformin; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2015 |
Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cohort Studies; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Severity of Illness Index; Survival Rate; Treatment Outcome | 2015 |
Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Base Sequence; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; p21-Activated Kinases; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sequence Homology, Nucleic Acid | 2015 |
Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Gene Knockdown Techniques; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Kaplan-Meier Estimate; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Glandular and Epithelial; Omeprazole; Ovarian Neoplasms; Paclitaxel; Proton Pump Inhibitors; RNA, Small Interfering; Transfection; Vacuolar Proton-Translocating ATPases; Xenograft Model Antitumor Assays | 2015 |
Restoration of paclitaxel resistance by CDK1 intervention in drug-resistant ovarian cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzazepines; Carcinoma, Ovarian Epithelial; CDC2 Protein Kinase; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Female; Humans; Indoles; Mice, Inbred C57BL; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2015 |
Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma.
Topics: Adipokines; Adult; Aged; Analysis of Variance; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Chitinase-3-Like Protein 1; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Lectins; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Glandular and Epithelial; Outcome Assessment, Health Care; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference | 2015 |
A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Retrospective Studies; Young Adult | 2016 |
Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Mice; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quinazolines | 2015 |
miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Signal Transduction; X-Linked Inhibitor of Apoptosis Protein | 2016 |
Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.
Topics: Adenoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cytoreduction Surgical Procedures; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; M Phase Cell Cycle Checkpoints; Membrane Proteins; Mice; Mice, Inbred BALB C; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Tumor Stem Cell Assay | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Front-Line Systemic Therapy of Newly Diagnosed Advanced Epithelial Ovarian Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Parenteral; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Polyethylene Glycols; Singapore | 2015 |
Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma.
Topics: Acyclic Monoterpenes; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Membrane Potential, Mitochondrial; Mice; Monoterpenes; Nanoparticles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reactive Oxygen Species; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
Topics: Actins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Carrier Proteins; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Formins; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Spheroids, Cellular; Thiones; Uracil | 2016 |
Clinical Practice of Adjuvant Chemotherapy in Patients with Early-Stage Epithelial Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models | 2016 |
Prognostic role of excision repair cross complementing-1 and topoisomerase-1 expression in epithelial ovarian cancer.
Topics: Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Cytoreduction Surgical Procedures; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proto-Oncogene Proteins c-myc; Survival Rate; tau Proteins; Tumor Suppressor Protein p53 | 2016 |
Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Propensity Score; Prospective Studies; Treatment Outcome | 2016 |
Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Cyclophosphamide; DNA Copy Number Variations; Female; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Homologous Recombination; Humans; Kaplan-Meier Estimate; Middle Aged; Mutation; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Sequence Analysis, DNA; Treatment Outcome; Tumor Suppressor Protein p53 | 2016 |
Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Case-Control Studies; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2016 |
Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Female; Humans; Lymphocyte Count; Membrane Proteins; Middle Aged; Monocytes; Neoplasms, Glandular and Epithelial; Neutrophils; Ovarian Neoplasms; Paclitaxel; Platelet Count; Retrospective Studies; Treatment Outcome | 2016 |
Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Ethnicity; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Racial Groups; Young Adult | 2016 |
Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C/IV ovarian cancer. Is there any difference?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2016 |
The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Taxoids | 2016 |
Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Female; Humans; Ketoconazole; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phthalic Acids; Pregnane X Receptor; Pregnenolone; Receptors, Steroid; RNA, Small Interfering; Signal Transduction | 2016 |
Paraaortic node recurrence 25 years after removal of epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Lymphoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Remission Induction; Treatment Outcome | 2016 |
Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2016 |
NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Chemokines; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorescent Antibody Technique; Growth Differentiation Factor 15; Humans; Immunohistochemistry; Inflammation; Kaplan-Meier Estimate; MAP Kinase Kinase Kinases; Microscopy, Confocal; Myeloid Differentiation Factor 88; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; NF-kappa B; Ovarian Neoplasms; Ovary; Paclitaxel; Prognosis; Signal Transduction; Smad4 Protein; Sulindac; Up-Regulation | 2016 |
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Agents; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Time Factors | 2016 |
Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Case-Control Studies; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Laparoscopy; Laparotomy; Middle Aged; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Neoplasm Grading; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Retrospective Studies | 2016 |
The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Cytoreduction Surgical Procedures; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Survival Rate; Time Factors | 2016 |
Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Comorbidity; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate | 2017 |
Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Germany; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Postoperative Complications; Retrospective Studies; Severity of Illness Index; Survival Rate; Young Adult | 2017 |
Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.
Topics: Adult; Animals; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carboplatin; Carcinoma, Ovarian Epithelial; Disease Models, Animal; Drug Evaluation, Preclinical; ErbB Receptors; Female; Genomic Instability; Heterografts; Humans; Mice; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Translational Research, Biomedical; Xenograft Model Antitumor Assays | 2017 |
Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial.
Topics: Administration, Intravenous; Anemia; Antineoplastic Agents; Blood Transfusion; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Decision Support Techniques; Disease-Free Survival; Drug Costs; Female; Filgrastim; Hematologic Agents; Hospitalization; Humans; Markov Chains; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proportional Hazards Models; Randomized Controlled Trials as Topic | 2017 |
Yin yang 1 modulates taxane response in epithelial ovarian cancer.
Topics: Antineoplastic Agents, Phytogenic; Binding Sites; Cell Movement; Cell Proliferation; Cisplatin; Comparative Genomic Hybridization; Docetaxel; E2F Transcription Factors; Epigenesis, Genetic; Female; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Neoplasms, Glandular and Epithelial; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survival Rate; Taxoids; Wound Healing; YY1 Transcription Factor | 2009 |
The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Mice; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2010 |
Glycoproteomics of paclitaxel resistance in human epithelial ovarian cancer cell lines: towards the identification of putative biomarkers.
Topics: Biomarkers; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Glycoproteins; HSP40 Heat-Shock Proteins; Humans; Membrane Glycoproteins; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proteomics; Thiolester Hydrolases; Triose-Phosphate Isomerase; Up-Regulation | 2010 |
Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Basigin; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; Female; Humans; Neoplasm Invasiveness; Neoplasms, Glandular and Epithelial; Oligodeoxyribonucleotides; Ovarian Neoplasms; Paclitaxel; STAT3 Transcription Factor; Transfection | 2010 |
The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomimetics; Cell Line; Cisplatin; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Female; Immunoblotting; Mice; Mice, Inbred C57BL; Morbidity; Neoplasms, Glandular and Epithelial; Oligopeptides; Ovarian Neoplasms; Paclitaxel; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Thrombospondin 1; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Characterisation of a multimeric protein complex associated with ERp57 within the nucleus in paclitaxel-sensitive and -resistant epithelial ovarian cancer cells: the involvement of specific conformational states of beta-actin.
Topics: Actins; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Nucleus; Chromosome Segregation; Drug Resistance, Neoplasm; Female; Humans; Multiprotein Complexes; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Protein Binding; Protein Conformation; Protein Disulfide-Isomerases; Protein Multimerization; Structure-Activity Relationship | 2010 |
Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Humans; Ki-67 Antigen; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Xenograft Model Antitumor Assays | 2010 |
Ovarian cancer care: it's time for "personalized" approaches.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; CA-125 Antigen; Carboplatin; Doxorubicin; Early Detection of Cancer; Female; Humans; Infusions, Parenteral; Membrane Proteins; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Patient Selection | 2010 |
Challenges to the paclitaxel/carboplatin algorithm in ovarian cancer treatment.
Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Genes, BRCA1; Genes, BRCA2; Humans; Infusions, Intravenous; Infusions, Parenteral; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Patient Selection; Poly Adenosine Diphosphate Ribose; Proteins | 2010 |
Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brachytherapy; Brain Neoplasms; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Role of gamma-synuclein in microtubule regulation.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Cytoskeleton; Female; Fluorescent Antibody Technique; gamma-Synuclein; Humans; Microtubule-Associated Proteins; Microtubules; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Tubulin; Tumor Cells, Cultured | 2011 |
C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carboplatin; Carcinoma, Ovarian Epithelial; Cells, Cultured; Claudin-4; Clostridium perfringens; Enterotoxins; Epithelial Cells; Female; Fluorescent Antibody Technique; Humans; In Situ Nick-End Labeling; Membrane Proteins; Mice; Mice, SCID; Neoplasms, Glandular and Epithelial; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Polymerase Chain Reaction; Proteasome Endopeptidase Complex; RNA, Messenger; Tight Junctions; Ubiquitin-Protein Ligase Complexes; Xenograft Model Antitumor Assays | 2011 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgical; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Hysterectomy; Kaplan-Meier Estimate; Length of Stay; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Statistics, Nonparametric; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2011 |
Synergistic growth-inhibitory effects of fenretinide with either cisplatin or paclitaxel on human epithelial ovarian cancer cell line (SKOV-3).
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Growth Processes; Cisplatin; Drug Interactions; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fenretinide; Growth Inhibitors; Humans; Inhibitory Concentration 50; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2004 |
Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cofilin 1; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Laparotomy; Microdissection; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2011 |
Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate | 2011 |
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Disease-Free Survival; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Topotecan | 2011 |
Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2011 |
Complementary and alternative medicine use among women receiving chemotherapy for ovarian cancer in 2 patient populations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Carboplatin; Carcinoma, Ovarian Epithelial; Complementary Therapies; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Surveys and Questionnaires; Survival Rate; Treatment Outcome; United Kingdom | 2011 |
The changes in residual cancer burden after interval debulking surgery are effective in evaluating the response to adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies | 2011 |
MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Female; Humans; MicroRNAs; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2011 |
Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Risk Factors; Taxoids; Young Adult | 2011 |
Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Female; Humans; Markov Chains; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2011 |
Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis | 2011 |
Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Cohort Studies; Disease-Free Survival; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Proteins; Serum; WAP Four-Disulfide Core Domain Protein 2 | 2012 |
Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: report of two cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Fatal Outcome; Female; Genes, BRCA1; Heterozygote; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Neoplasms, Glandular and Epithelial; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Platinum | 2012 |
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Humans; Intestinal Fistula; Intestinal Perforation; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Rectovaginal Fistula; Retrospective Studies; Taxoids; Treatment Outcome; Urinary Bladder Fistula; Vascular Endothelial Growth Factor A; Vinblastine; Vinorelbine | 2011 |
Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Male; Middle Aged; Models, Statistical; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Regression Analysis; Time Factors; Treatment Outcome | 2012 |
Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Topics: 3' Untranslated Regions; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Calcium-Binding Proteins; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Cycle Proteins; Cell Line, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mad2 Proteins; MicroRNAs; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Paraffin Embedding; Proportional Hazards Models; Repressor Proteins; Retrospective Studies; Risk Assessment; Risk Factors; RNA Interference; Time Factors; Transfection; Treatment Outcome | 2012 |
Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Pennsylvania; Registries; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cations; Drug Delivery Systems; Female; Humans; KB Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Glandular and Epithelial; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2012 |
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
Topics: 3' Untranslated Regions; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Carboplatin; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Genotype; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; RNA Interference; Treatment Outcome | 2012 |
Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Disease-Free Survival; DNA-Binding Proteins; DNA, Neoplasm; Endonucleases; Female; Genotype; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Paraffin Embedding; Polymorphism, Single Nucleotide; Predictive Value of Tests; Randomized Controlled Trials as Topic; Young Adult | 2012 |
Prognostic value of biomarkers related to drug resistance in patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2012 |
Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Caspase 3; Cell Line, Tumor; Cisplatin; Elafin; Female; Fluorouracil; Gene Knockdown Techniques; Gene Silencing; Humans; Mice; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Transfection | 2012 |
Secondary cytoreductive surgery outcomes of selected patients with paclitaxel/platinum sensitive recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Treatment Outcome | 2012 |
Evaluation of whether serum tumor markers in patients with epithelial ovarian carcinoma change following chemotherapy.
Topics: Aged; Biomarkers, Tumor; CA-125 Antigen; CA-19-9 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2012 |
Advances in epithelial ovarian cancer therapy.
Topics: Antineoplastic Agents; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2012 |
Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cohort Studies; Drug Administration Schedule; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Disease Progression; Female; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Vascular Endothelial Growth Factor A | 2012 |
[The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Repressor Proteins; RNA, Messenger; Tubulin | 2012 |
Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Aptamers, Nucleotide; Artificial Gene Fusion; Base Sequence; Carcinoma, Ovarian Epithelial; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Molecular Sequence Data; Mucin-1; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Signal Transduction | 2012 |
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Etoposide; Female; Half-Life; Humans; Irinotecan; Linear Models; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Reference Values; Remission Induction; Taxoids | 2012 |
Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Female; Fibroblasts; Humans; Immunohistochemistry; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2012 |
Doublet chemotherapy in the elderly patient with ovarian cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Clinical Trials as Topic; Female; Geriatric Assessment; Humans; Injections, Intraperitoneal; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2012 |
Establishment of paclitaxel-resistant cell line and the underlying mechanism on drug resistance.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Microarray Analysis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Signal Transduction | 2012 |
The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies | 2013 |
[Effect of evidence-based medicine on the decision of chemotherapy for epithelial ovarian cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Administration Routes; Evidence-Based Medicine; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 2012 |
The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2013 |
Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.
Topics: Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Synergism; Female; Humans; Inhibitor of Apoptosis Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Necrosis; Neoplasms, Glandular and Epithelial; Oligopeptides; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Skin; Survivin; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein | 2013 |
A case of occult bowel perforation after a cycle of chemotherapy for advanced epithelial ovarian carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Intestinal Perforation; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel | 2012 |
Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Blood Proteins; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Regulatory Networks; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Principal Component Analysis; ROC Curve; Taxoids; Transcriptome | 2012 |
Epigenetic silencing of BLU through interfering apoptosis results in chemoresistance and poor prognosis of ovarian serous carcinoma patients.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Cytoskeletal Proteins; Drug Resistance, Neoplasm; Epigenomics; Female; Gene Silencing; Humans; Methylation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; RNA, Small Interfering; Tumor Suppressor Proteins | 2013 |
Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Aurora Kinase A; Azepines; Carcinoma, Ovarian Epithelial; Cell Adhesion; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Female; Humans; Mice; Mitosis; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; RNA Interference; RNA, Small Interfering; src-Family Kinases; Xenograft Model Antitumor Assays | 2014 |
Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Middle Aged; Neoplasms, Glandular and Epithelial; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; RNA Interference; RNA, Small Interfering; Treatment Failure; Xenograft Model Antitumor Assays | 2012 |
Dose-dense paclitaxel with carboplatin for advanced ovarian cancer: a feasible treatment alternative.
Topics: Alberta; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recombinant Proteins; Survival Rate | 2013 |
Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; RNA, Small Interfering; Survivin; Young Adult | 2013 |
Extraorbital sebaceous carcinoma with rapidly developing visceral metastases.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Fatal Outcome; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Orbit; Paclitaxel; Sebaceous Gland Neoplasms; Taxoids; Viscera | 2003 |
Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Practice Guidelines as Topic; Prospective Studies; Radiotherapy Dosage; Survival Rate; Taxoids | 2003 |
[A retrospective study of advanced ovarian cancer in our ward].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2003 |
Topotecan versus paclitaxel in second-line therapy: a lost opportunity for quality-of-life evaluation?
Topics: Antineoplastic Agents; Female; Follow-Up Studies; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Quality of Life; Time Factors; Topotecan; Treatment Outcome | 2004 |
Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Time Factors | 2005 |
Significance of the O6-methylguanine-DNA methyltransferase and glutathione S-transferase activity in the sera of patients with malignant and benign ovarian tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cisplatin; Female; Glutathione Transferase; Gynecologic Surgical Procedures; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; O(6)-Methylguanine-DNA Methyltransferase; Ovarian Neoplasms; Paclitaxel | 2005 |
Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Carrier Proteins; Cell Line; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gene Expression Regulation; Genes, ras; Humans; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Knockout; Neoplasms, Glandular and Epithelial; Paclitaxel; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyrazines; Tumor Suppressor Protein p53 | 2005 |
Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross-Sectional Studies; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Hematologic Diseases; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2005 |
Non-enrolment of ovarian cancer patients in clinical trials: reasons and background.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Patient Participation; Patient Selection; Prospective Studies; Retrospective Studies; Topotecan | 2005 |
Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers?
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Female; Heterocyclic Compounds, 1-Ring; Humans; Immunoglobulin G; Indium Radioisotopes; Male; Mammary Neoplasms, Experimental; Mice; Neoplasm Transplantation; Neoplasms, Glandular and Epithelial; Paclitaxel; Prostatic Neoplasms; Radioimmunotherapy; Time Factors | 2005 |
Epithelial-myoepithelial carcinoma of the submandibular gland with symptomatic lung metastases treated with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Fatal Outcome; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Myoepithelioma; Neoplasms, Glandular and Epithelial; Paclitaxel; Radiotherapy Dosage; Submandibular Gland Neoplasms | 2006 |
Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2006 |
Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Doxorubicin; Female; Humans; Markov Chains; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Topotecan | 2007 |
Developmental chemotherapy and management of recurrent ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2003 |
Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Membrane Permeability; Cisplatin; Female; Gastrointestinal Tract; Humans; Intestinal Absorption; Lactulose; Mannitol; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Sucrose; Trastuzumab; Xylose | 2007 |
ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; DNA-Binding Proteins; Endonucleases; Female; Genotype; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phenotype; RNA, Messenger | 2007 |
Ovarian cancer.
Topics: Female; Humans; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Survival Rate; United States | 1994 |
Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Drug Resistance; Female; Gene Expression; Humans; Molecular Sequence Data; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Tubulin; Tumor Cells, Cultured | 1997 |
A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Digestive System; Female; Humans; Middle Aged; Necrosis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel | 1997 |
[A case of epithelial cancer of the alveoli which responded favorably to the additional administration of UFT for refractory cancer after administration of carboplatin and docetaxel].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Paclitaxel; Pulmonary Alveoli; Taxoids; Tegafur; Uracil | 2000 |
Biological basis for chemo-radiotherapy interactions.
Topics: Antineoplastic Agents; Apoptosis; Cell Transformation, Neoplastic; Cisplatin; Combined Modality Therapy; Deoxycytidine; DNA Adducts; DNA Repair; Docetaxel; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Paclitaxel; Radiotherapy; Taxoids | 2002 |